An Expanded Access, Open-Label Study of Trastuzumab-MCC-DM1 Administered Intravenously to Patients With HER2- Positive Locally Advanced or Metastatic Breast Cancer.

Trial Profile

An Expanded Access, Open-Label Study of Trastuzumab-MCC-DM1 Administered Intravenously to Patients With HER2- Positive Locally Advanced or Metastatic Breast Cancer.

Active, no longer recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 18 Feb 2017

At a glance

  • Drugs Trastuzumab emtansine (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Expanded access
  • Acronyms T-PAS
  • Sponsors Genentech
  • Most Recent Events

    • 13 Feb 2017 Status changed from completed to active, no longer recruiting.
    • 09 Sep 2013 Results presented at the 2013 Breast Cancer Symposium.
    • 09 May 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top